白蛋白结合型紫杉醇与吉西他滨在晚期肺鳞癌中的疗效观察  

Efficacy of albumin-bound paclitaxel and gemcitabine in advanced squamous cell lung carcinoma

作　　者：彭黎明 陈凤舞 罗丹 PENG Liming;CHEN Fengwu;LUO Dan(Oncology Department,Yichun People′s Hospital in Jiangxi Province,Yichun336000,China;Radiotherapy Department,Yichun People′s Hospital in Jiangxi Province,Yichun336000,China)

机构地区：[1]江西省宜春市人民医院肿瘤科,江西宜春336000 [2]江西省宜春市人民医院放疗科,江西宜春336000

出　　处：《中国现代医生》2021年第26期111-114,共4页China Modern Doctor

基　　金：江西省宜春市科技计划指导性项目(JXYC2021KSA018)。

摘　　要：目的 比较白蛋白结合型紫杉醇(Abraxane)与吉西他滨在晚期肺鳞癌中的疗效。方法 纳入2019年1月至2020年1月我院接诊的40例晚期肺鳞癌患者作为研究对象。按照随机数字表法分为A组和B组,每组各20例。A组接受Abraxane联合奈达铂治疗,B组接受吉西他滨联合奈达铂治疗。比较两组患者的临床疗效、不良反应发生情况以及无进展生存期(PFS)、1年生存率。结果 A组患者治疗总有效率和疾病控制率均略高于B组,差异无统计学意义(P>0.05);A组患者胃肠反应、骨髓抑制发生率及严重程度均低于B组,差异有统计学意义(P<0.05);A组患者无进展生存期长于B组,差异有统计学意义(P<0.05);A组患者1年生存率略高于B组,差异无统计学意义(P>0.05)。结论 Abraxane在晚期肺鳞癌中效果优于吉西他滨,且不良反应更少,可作为优选药物搭配奈达铂进行晚期肺鳞癌的治疗。Objective To compare the efficacy of albumin-bound paclitaxel and gemcitabine in advanced squamous cell lung carcinoma.Methods A total of 40 patients with advanced squamous cell lung carcinoma who were admitted to our hospital from January 2019 to January 2020 were included and divided into group A and group B according to the random number table control method,with 20 cases in each group.The patients in group A were treated with albumin-bound paclitaxel combined with nedaplatin,and the patients in group B were treated with gemcitabine combined with nedaplatin.The clinical efficacy,adverse reactions,progression free survival(PFS)and 1-year survival rate in the two groups were compared.Results The total response rates and disease control rates of patients were slightly higher in group A than those in group B,and the differences were not statistically significant(P>0.05).The gastrointestinal reactions,the incidences and severities of myelosuppression were lower in group A than those in group B,and the differences were statistically significant(P<0.05).The progression free survival of patients was longer in group A than that in group B,and the difference was statistically significant(P<0.05).The 1-year survival rate of patients was slightly higher in group A than that in group B,and the difference was not statistically significant(P>0.05).Conclusion Albumin-bound paclitaxel is more effective than gemcitabine in advanced squamous cell lung carcinoma with fewer adverse reactions,and can be used as the preferred drug paired with nedaplatin for the treatment of advanced squamous cell lung carcinoma.

关 键 词：晚期肺鳞癌 ABRAXANE 吉西他滨 奈达铂 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]